Texas Sues Eli Lilly Over Alleged Provider Bribes for GLP-1 Drugs

Texas Attorney General Ken Paxton filed a lawsuit on Tuesday against Eli Lilly, accusing the U.S. drugmaker of bribing and illegally inducing healthcare providers to prescribe its most profitable medicines. The complaint, lodged in a Texas state court, alleges the company offered kickbacks tied to its GLP-1 medications Mounjaro and Zepbound, which are widely used to treat diabetes and for weight loss. "Big Pharma compromised medical decision-making by engaging in an illegal kickback scheme," Paxton said in a statement. The action extends Paxton’s campaign to challenge pharmaceutical marketing practices; last year he sued insulin makers and pharmacy benefit managers over alleged price manipulation. The latest filing comes amid broader federal and state scrutiny of the booming GLP-1 market.